ArticleNature aging2021
SARS-CoV-2, COVID-19 and the Ageing Immune System.
Article in Nature aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
228 citing papers in PubMed, 354 citations in OpenAlex.
- Trial
- Counting cases, conserving species: addressing highly pathogenic avian influenza in wildlife.Biological reviews of the Cambridge Philosophical Society · 2026Review
- Integration of the circulating miRNome and clinical information to predict 90-day mortality in elderly COVID-19 subphenotypes.iScience · 2026Article
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study.Nature communications · 2026Article
- Risk Factors and Vaccination Dose Associated with COVID-19 Mortality: A Population-Based Study in Gyeongsangbuk-do, South Korea.Pathogens (Basel, Switzerland) · 2026Article
- Immune aging biomarkers for clinical trials.Nature medicine · 2026Review
- Longitudinal humoral and memory B-cell responses to repeated SARS-CoV-2 vaccination in long-term care facilities residents.Immunity & ageing : I & A · 2026Article
- Large-scale genomic surveillance reveals immunosuppression drives mutation dynamics in persistent SARS-CoV-2 infections.Nature communications · 2026Article
- Risk factors for intensive care unit coronavirus disease 2019 pneumonia-associated invasive fungal infections: a Bayesian evidence synthesis integrating external and real-world data.Virology journal · 2026Article
- Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.BMC medicine · 2026Review
- Sex- and Age-Dependent Neuroimmune Dysregulation and Early Neurodegenerative Signatures Following SARS-CoV-2 Infection in Golden Syrian Hamsters.Research square · 2026Article
- Attenuating age-related decline in dendritic cell migration improves vaccine efficacy via gut-immune crosstalk.Nature aging · 2026Article
- Weathering the Double Storm-Resilience in Chinese Older Cancer Patients With Long COVID: A Qualitative Study.Journal of advanced nursing · 2026Article
- The case for space as a model of accelerated aging.Nature aging · 2026Review
- A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatio-temporal trends in COVID-19 morbidity and mortality due to elderly: a global perspective.Scientific reports · 2026Article
- B cells drive CD4 T cell immunosenescence and age-associated health decline.Science immunology · 2026Article
- Observational
- Observational
168 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is a global health threat with particular risk for severe disease and death in older adults and in adults with age-related metabolic and cardiovascular disease. Recent advances in the science of ageing have highlighted how ageing pathways control not only lifespan but also healthspan, the healthy years of life. Here, we discuss the ageing immune system and its ability to respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We specifically focus on the intersect of severe COVID-19 and immunosenescence to highlight pathways that may be determinant for the risk of complications and death following infection with SARS-CoV-2. New or adapted therapeutics that target ageing-associated pathways may be important tools to reduce the burden of death and long-term disability caused by this pandemic. Proposed interventions aimed at immunosenescence could enhance immune function not only in the elderly but in susceptible younger individuals as well, ultimately improving complications of severe COVID-19 for all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.